Literature DB >> 19193847

Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests.

Carolina Garrido1, Natalia Zahonero, Angélica Corral, Miguel Arredondo, Vincent Soriano, Carmen de Mendoza.   

Abstract

The plasma human immunodeficiency virus (HIV) RNA load is used in the clinical routine for the monitoring of HIV infection and the patient's response to antiretroviral therapy. Other body fluids or dried blood spots (DBS) can be used, however, to assess the level of viremia. The use of DBS may be especially helpful for the monitoring of HIV-infected patients in resource-poor settings, where access to adequate laboratory facilities is often difficult. However, the correlation between the HIV RNA levels in plasma and those in DBSs has not been well established. Paired plasma and DBS samples obtained from HIV type 1 (HIV-1)-infected patients were tested for HIV RNA copy numbers by using two different commercial assays, the Nuclisens EasyQ HIV-1 (version 1.1) test (the Nuclisens test; Biomerieux) and the m2000rt RealTime HIV test (the m2000rt test; Abbott). Nucleic acid extraction was performed manually by using either the Nuclisens isolation kit (which uses the Boom methodology) or the m2000rt sample preparation kit (an iron particle-based method). A total of 103 paired plasma and DBS samples were tested. Viral load results were obtained for 97 (94.2%) samples with the Nuclisens isolation kit and 81 (78.6%) samples with the m2000rt kit. The overall correlation between the RNA loads in plasma and DBS was good, although better results were obtained by the Nuclisens test (R(2) = 0.87, P < 0.001) than by the m2000rt test (R(2) = 0.70, P < 0.001). While the specificities were excellent and similar for both the Nuclisens and the m2000rt tests (97.1% and 100%, respectively), the sensitivity was greater by the Nuclisens test than by the m2000rt test (75.8% and 56.6%, respectively). Overall, the viral loads in DBS tended to be lower than those in plasma, with mean differences of 0.3 log unit (standard deviation, 0.5 log unit) and 0.76 log unit (standard deviation, 0.8 log unit) for the Nuclisens and the m2000rt tests, respectively. The levels of agreement between the measurements in plasma and DBS were assessed by using the Bland-Altman plot for each assay. The Nuclisens test gave results within its defined limits (-0.65 to 1.26) for 95.9% of the samples, while the m2000rt test gave results within its limits (-0.83 to 2.33) for 100% of the samples. In summary, the HIV-1 load can accurately be quantified by testing DBS by either the Nuclisens or the m2000rt test, although the Nuclisens test may outperform the m2000rt test when nucleic acids are extracted manually.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19193847      PMCID: PMC2668340          DOI: 10.1128/JCM.02099-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Usage of dried blood spots for molecular diagnosis and monitoring HIV-1 infection.

Authors:  Sumonmal Uttayamakul; Sirirat Likanonsakul; Rujanee Sunthornkachit; Karoon Kuntiranont; Suda Louisirirotchanakul; Achara Chaovavanich; Vipa Thiamchai; Sombat Tanprasertsuk; Ruengpung Sutthent
Journal:  J Virol Methods       Date:  2005-09       Impact factor: 2.014

2.  Comparison of the COBAS TAQMAN HIV-1 HPS with VERSANT HIV-1 RNA 3.0 assay (bDNA) for plasma RNA quantitation in different HIV-1 subtypes.

Authors:  Perpétua Gomes; Ana Carolina Palma; Joaquim Cabanas; Ana Abecasis; Ana Patrícia Carvalho; Rainer Ziermann; Isabel Diogo; Fátima Gonçalves; Céu Sousa Lobo; Ricardo Camacho
Journal:  J Virol Methods       Date:  2006-05-03       Impact factor: 2.014

3.  Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparison to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5, and LCx HIV RNA Quantitative assays.

Authors:  Priscilla Swanson; Vera Holzmayer; Shihai Huang; Phillip Hay; Ade Adebiyi; Philip Rice; Klara Abravaya; Sven Thamm; Sushil G Devare; John Hackett
Journal:  J Virol Methods       Date:  2006-07-28       Impact factor: 2.014

4.  Use of dried spots of whole blood, plasma, and mother's milk collected on filter paper for measurement of human immunodeficiency virus type 1 burden.

Authors:  Workenesh Ayele; Rob Schuurman; Tsehaynesh Messele; Wendelien Dorigo-Zetsma; Yohannes Mengistu; Jaap Goudsmit; William A Paxton; Michel P de Baar; Georgios Pollakis
Journal:  J Clin Microbiol       Date:  2007-01-24       Impact factor: 5.948

5.  HIV-1 drug resistance surveillance using dried whole blood spots.

Authors:  Silvia Bertagnolio; Luis Soto-Ramirez; Richard Pilon; Roberto Rodriguez; Monica Viveros; Luis Fuentes; P Richard Harrigan; Theresa Mo; Don Sutherland; Paul Sandstrom
Journal:  Antivir Ther       Date:  2007

6.  Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study.

Authors:  Rita Murri; Alessandro Cozzi Lepri; Paola Cicconi; Antonio Poggio; Massimo Arlotti; Giulia Tositti; Domenico Santoro; Maria Luisa Soranzo; Giuliano Rizzardini; Vincenzo Colangeli; Maria Montroni; Antonella D'Arminio Monforte
Journal:  J Acquir Immune Defic Syndr       Date:  2006-01-01       Impact factor: 3.731

7.  Evaluation of the dried blood spot filter paper technology and five testing strategies of HIV-1 and HIV-2 infections in West Africa.

Authors:  Ramu Sarge-Njie; Maarten Schim Van Der Loeff; Saihou Ceesay; David Cubitt; Saihou Sabally; Tumani Corrah; Hilton Whittle
Journal:  Scand J Infect Dis       Date:  2006

8.  High correlation of human immunodeficiency virus type-1 viral load measured in dried-blood spot samples and in plasma under different storage conditions.

Authors:  Ma Tereza Alvarez-Muñoz; Silvia Zaragoza-Rodríguez; Othón Rojas-Montes; Gerardo Palacios-Saucedo; Guillermo Vázquez-Rosales; Alejandro Gómez-Delgado; Javier Torres; Onofre Muñoz
Journal:  Arch Med Res       Date:  2005 Jul-Aug       Impact factor: 2.235

9.  Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry.

Authors:  Therese Koal; Heike Burhenne; Regina Römling; Michal Svoboda; Klaus Resch; Volkhard Kaever
Journal:  Rapid Commun Mass Spectrom       Date:  2005       Impact factor: 2.419

10.  Comparative evaluation of the performance of the Abbott real-time human immunodeficiency virus type 1 (HIV-1) assay for measurement of HIV-1 plasma viral load following automated specimen preparation.

Authors:  A Garcia-Diaz; G S Clewley; C L Booth; W Labett; N McAllister; A M Geretti
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

View more
  34 in total

1.  Evaluation of a high-throughput diagnostic system for detection of HIV-1 in dried blood spot samples from infants in Mozambique.

Authors:  Ilesh V Jani; Jennifer Sabatier; Adolfo Vubil; Shambavi Subbarao; Dulce Bila; Amina de Sousa; Nédio Mabunda; Albert Garcia; Beth Skaggs; Dennis Ellenberger; Artur Ramos
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

2.  HIV load testing with small samples of whole blood.

Authors:  Katrin Steinmetzer; Thomas Seidel; Andreas Stallmach; Eugen Ermantraut
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

3.  Higher specificity of nucleic acid sequence-based amplification isothermal technology than of real-time PCR for quantification of HIV-1 RNA on dried blood spots.

Authors:  Severine Mercier-Delarue; Muriel Vray; Jean Christophe Plantier; Theodora Maillard; Zidan Adjout; Fabienne de Olivera; Nathalie Schnepf; Sarah Maylin; Francois Simon; Constance Delaugerre
Journal:  J Clin Microbiol       Date:  2013-10-16       Impact factor: 5.948

4.  Leukodepletion as a point-of-care method for monitoring HIV-1 viral load in whole blood.

Authors:  Logan Titchmarsh; Clement Zeh; Thierry Verpoort; Jean-Pierre Allain; Helen Lee
Journal:  J Clin Microbiol       Date:  2014-11-26       Impact factor: 5.948

5.  Laser cutting eliminates nucleic acid cross-contamination in dried-blood-spot processing.

Authors:  Sean C Murphy; Glenda Daza; Ming Chang; Robert Coombs
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

Review 6.  The Diagnosis of HIV Infection in Infants and Children.

Authors:  Alireza Abdollahi; Hana Saffar
Journal:  Iran J Pathol       Date:  2016

7.  Limited utility of dried-blood- and plasma spot-based screening for antiretroviral treatment failure with Cobas Ampliprep/TaqMan HIV-1 version 2.0.

Authors:  Souleymane Sawadogo; Andreas Shiningavamwe; Joy Chang; Andrew D Maher; Guoqing Zhang; Chunfu Yang; Esegiel Gaeb; Harold Kaura; Dennis Ellenberger; David W Lowrance
Journal:  J Clin Microbiol       Date:  2014-08-20       Impact factor: 5.948

8.  Prospective evaluation of diagnostic accuracy of dried blood spots from finger prick samples for determination of HIV-1 load with the NucliSENS Easy-Q HIV-1 version 2.0 assay in Malawi.

Authors:  Emmanuel Fajardo; Carol A Metcalf; Pascale Chaillet; Lucia Aleixo; Pieter Pannus; Isabella Panunzi; Laura Triviño; Tom Ellman; Andrew Likaka; Reuben Mwenda
Journal:  J Clin Microbiol       Date:  2014-02-05       Impact factor: 5.948

9.  Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia.

Authors:  Marjorie Monleau; Avelin F Aghokeng; Sabrina Eymard-Duvernay; Anoumou Dagnra; Dramane Kania; Nicole Ngo-Giang-Huong; Coumba Touré-Kane; Lien X T Truong; Marie-Laure Chaix; Eric Delaporte; Ahidjo Ayouba; Martine Peeters
Journal:  J Clin Microbiol       Date:  2013-12-11       Impact factor: 5.948

10.  Post-extraction stabilization of HIV viral RNA for quantitative molecular tests.

Authors:  Daniel S Stevens; Christopher H Crudder; Gonzalo J Domingo
Journal:  J Virol Methods       Date:  2012-03-13       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.